DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021071/S-040
NDA 021410/S-029
NDA 021700/S-012

SUPPLEMENT APPROVAL

SB Pharmco Puerto Rico, Inc (d/b/a/GlaxoSmithKline)
Attention: Margaret M. Kreider, Ph.D.
Director, Therapeutic Area, Regulatory Affairs
2301 Renaissance Blvd.
King of Prussia, PA 19406-2772

Dear Dr. Kreider:

Please refer to your Supplemental New Drug Applications (sNDA) dated October 31, 2011, received October 31, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), for AVANDIA (rosiglitazone maleate) Tablets, AVANDARYL (rosiglitazone maleate and glimepiride) Tablets, and AVANDAMET (rosiglitazone maleate and metformin hydrochloride) Tablets.

We acknowledge receipt of your amendment dated November 9, 2011. We also acknowledge receipt of your risk evaluation and mitigation strategy (REMS) assessment contained in these submissions. After consultation between the Office of New Drugs and the Office of Surveillance and Epidemiology, we have found the REMS assessment to be adequate.

These supplemental new drug applications provide for proposed modifications to the approved Rosiglitazone REMS.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for AVANDIA (rosiglitazone maleate) was originally approved on May 18, 2011. The REMS for AVANDARYL (rosiglitazone maleate and glimepiride) and AVANDAMET (rosiglitazone maleate and metformin hydrochloride) was originally approved on December 2, 2008, and modified on May 18, 2011. The Rosiglitazone REMS consists of a Medication Guide, a communication plan, elements to assure safe use (ETASU), an implementation system, and a timetable for submission of assessments of the REMS. Your proposed modification to the REMS consists of a revised communication plan adding a message to the REMS website to communicate the requirement for patients to be enrolled in the Rosiglitazone REMS Program in order to continue to receive Avandia medicines, and maintaining that message on the website through the first quarter of 2012.

Your proposed modified REMS, submitted and received on October 31, 2011, and appended to this letter, is **approved**.

The timetable for submission of assessments of the REMS will remain the same as that approved on May 18, 2011.

There are no changes to the REMS assessment plan described in our May 18, 2011, REMS approval letters for these products.

We remind you that assessments of an approved REMS must also include, under section 505-1(g)(3)(B) and (C), information on the status of any postapproval study or clinical trial required under section 505(o) or otherwise undertaken to investigate a safety issue. With respect to any such postapproval study, you must include the status of such study, including whether any difficulties completing the study have been encountered. With respect to any such postapproval clinical trial, you must include the status of such clinical trial, including whether enrollment has begun, the number of participants enrolled, the expected completion date, whether any difficulties completing the clinical trial have been encountered, and registration information with respect to requirements under subsections (i) and (j) of section 402 of the Public Health Service Act. You can satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 314.81(b)(2)(vii) and including any material or significant updates to the status information since the annual report was prepared. Failure to comply with the REMS assessments provisions in section 505-1(g) could result in enforcement action.

In addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of FDCA.

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic REMS submission.

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

NDA 021071/ NDA 021410/ NDA 021700 REMS ASSESSMENT

NEW SUPPLEMENT FOR NDA 021071/ NDA 021410/ NDA 021700
PROPOSED REMS MODIFICATION
REMS ASSESSMENT

NEW SUPPLEMENT (NEW INDICATION FOR USE) FOR NDA 021071/ NDA 021410/ NDA 021700
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Jena Weber, Regulatory Project Manager, at 301-796-1306.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE: REMS and Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY H PARKS
11/13/2011